Medical Amino Acid Market Report 2025

The medical amino acid market size has grown strongly in recent years. It will grow from $3.8 billion in 2024 to $4.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increased prevalence of chronic diseases, rise in cases of metabolic disorders, increased geriatric population with special nutritional needs, increased demand for parenteral nutrition solutions, and rise in prevalence of gastrointestinal disorders.

The medical amino acid market size is expected to see strong growth in the next few years. It will grow to $5.57 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. Factors contributing to this growth include the broadening use in treating liver diseases, implementation in nutritional therapy for trauma and surgical patients, better detection of amino acid-related deficiencies, increased application in managing muscle-wasting diseases, and growing nutritional needs in neonatal and pediatric care. The forecast period is expected to witness key trends such as progress in amino acid synthesis technology, the emergence of specialized amino acid formulations, innovations in therapeutic amino acid-based foods, enhanced delivery techniques, and improvements in product shelf-life and absorption efficiency.

The rising incidence of liver diseases is expected to propel the growth of the medical amino acid market going forward. Liver disease is a broad term for disorders that negatively affect the liver's structure or function, disrupting its essential roles in the body. Liver diseases are rising due to increasing rates of obesity, which contribute to the development of non-alcoholic fatty liver disease as excess fat accumulates in liver cells and impairs their function. Medical amino acids manage liver-related metabolic imbalances and support liver cell regeneration, making them essential in nutritional therapy for affected patients. For instance, in July 2023, according to the British Liver Trust, a UK-based charitable organization, there was a 22% increase in hospital admissions primarily due to liver disease in the financial year ending 2022, with cases rising from 67,458 in 2021 to 82,290 in 2022. Therefore, the rising incidence of liver diseases drives the medical amino acid market.

Key players in the medical amino acid market are prioritizing the development of advanced offerings such as amino acid-based specialty formulas designed to reduce allergic responses. These specialty formulas are medical foods formulated with individual amino acids to fulfill the dietary requirements of patients with metabolic or absorption challenges. For example, in May 2022, Abbott, a U.S.-based healthcare and medical device company, introduced EleCare, a hypoallergenic amino acid-based nutritional formula. EleCare is intended for infants and children suffering from severe food allergies or digestive issues requiring amino acid-specific nutrition. It provides complete essential nutrients necessary for development from birth up to 12 months. This formula is particularly suited for individuals who cannot process whole or partially hydrolyzed proteins due to conditions like malabsorption, protein maldigestion, eosinophilic GI disorders, and short-bowel syndrome. Administered orally or via feeding tube, its use must be under medical supervision.

In October 2023, Grand Pharmaceutical Group Limited, based in Hong Kong, acquired Hubei Bafeng for $37.24 million (RMB 270 million). The acquisition is aimed at expanding Grand Pharmaceutical’s manufacturing capabilities and diversifying its offerings by incorporating Hubei Bafeng’s proficiency in amino acid active pharmaceutical ingredients (APIs) and clinical nutrition solutions. Hubei Bafeng is a China-based company specializing in medical amino acids.

Major players in the medical amino acid market are Cargill Inc., Archer Daniels Midland, Evonik Industries AG, Ajinomoto Co. Inc., Nippon Kayaku Co. Ltd., Kemin Industries Inc., Global Bio-Chem Technology Group Company Ltd., FUJIFILM Irvine Scientific, Nippon Rika Co. Ltd., Acuro Organica Limited, Ava Chemicals Pvt. Ltd., Kyowa Hakko Bio Co. Ltd., Wenda Co. Ltd., Catapharma Chemicals Pvt. Ltd., Chaitanya Group, Aelicure Pharma, KD Chem Pharma, Hexon Laboratories Pvt. Ltd., A B Enterprises, Shanghai Kyowa Amino Acid Co. Ltd.

North America was the largest region in the medical amino acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the medical amino acid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medical amino acid market consists of sales of amino acid blends, protein-free medical formulas, amino acid powders, and amino acid-based drinks. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The medical amino acid market research report is one of a series of new reports that provides medical amino acid market statistics, including medical amino acid industry global market size, regional shares, competitors with a medical amino acid market share, detailed medical amino acid market segments, market trends and opportunities, and any further data you may need to thrive in the medical amino acid industry. This medical amino acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Medical amino acids are specifically formulated amino acids intended to cater to particular physiological requirements, especially in people who have metabolic or health conditions that interfere with protein digestion or amino acid absorption. These amino acids are engineered to deliver exact nutritional value, ensuring a balanced supply of both essential and non-essential amino acids vital for the body’s development, healing, and maintenance processes.

The key product types in the medical amino acid market include L-glutamine, L-arginine, L-lysine, L-leucine, L-isoleucine, L-valine, and others. L-glutamine is a conditionally essential amino acid, implying that while the body generally produces adequate amounts, additional supplementation is needed during times of illness, injury, or physical stress. These are utilized in various applications such as medical supplements, medicinal foods, active pharmaceutical ingredients (API), pharmaceutical intermediates, and cell culture ingredients. These products serve numerous end-users including hospitals, research laboratories, clinics, pharmaceutical companies, and nutraceutical companies.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.